Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Palisade Bio, Inc. (PALI : NSDQ)

• Company Description    Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $1.33 Daily Weekly Monthly 20 Day Moving Average: 2,730,291 shares Shares Outstanding: 174.27 (millions) Market Capitalization: $231.78 (millions) Beta: 1.61 52 Week High: $2.86 52 Week Low: $1.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.29% -14.39% 12 Week -32.14% -33.80% Year To Date -43.40% -48.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4600 South Syracuse Street Suite 900 - Denver,CA 80237 USA ph: 858-704-4900 fax: - pali@jtcir.com http://www.palisadebio.com

• General Corporate Information    Officers J.D. Finley - Chief Executive Officer; Chief Financial Officer Donald A. Williams - Chairman Mitchell Jones - President Emil Chuang - Director Binxian Wei - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 696389402 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 174.27 Most Recent Split Date: 4.00 (0.07:1) Beta: 1.61 Market Capitalization: $231.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 91.38% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -33.47 03/31/26 - -36.79 ROA 09/30/26 - - 06/30/26 - -31.79 03/31/26 - -34.34 Current Ratio 09/30/26 - - 06/30/26 - 24.26 03/31/26 - 23.71 Quick Ratio 09/30/26 - - 06/30/26 - 24.26 03/31/26 - 23.71 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - -6,388.20 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 0.70 03/31/26 - 0.76 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©